A few years ago, (NYSE: PFE) saw revenue soar to record heights thanks to coronavirus-related sales, from its vaccine Comirnaty and its treatment Paxlovid. On top of this, the company's blockbuster drugs in other treatment areas were going strong. But in recent times, this pharma giant has been going through something of a transition.

In later stages of the pandemic, sales of coronavirus products flagged. To add to this bad news, investors focused on upcoming patent expirations for some of Pfizer's key products. As a result, Pfizer stock has fallen nearly 30% over the past five years.

But the company hasn't been sitting around as this story unfolds; instead, it's laid the groundwork for its next chapters. Where will they take Pfizer in five years? Let's find out.

Continue reading

Source Fool.com